Research Centre: Aquatic and Crop Resource Development, Automotive and Surface Transportation, Design and Fabrication services, Human Health Therapeutics, Industrial Research Assistance Program, Medical Devices
As the leading cause of birth defects, cytomegalovirus (CMV) affects more children than Fetal Alcohol Syndrome or Down Syndrome and infects up to 90 percent of adults worldwide. Typically unnoticed in healthy people, CMV can be life-threatening for the immunocompromised, which includes persons infected with HIV, organ transplant recipients and most commonly, newborn infants.
The inner workings of the human brain hold mysteries that continue to challenge medical researchers and scientists around the world. One such mystery is determining how to delay the progression of brain diseases such as Alzheimers, Multiple Sclerosis (MS) and Parkinsons. Now an important Canadian research breakthrough may have found the key to slowing their spread.
When Vancouver, B.C.'s Zymeworks Inc. opened its doors in 2003, the biotherapeutics company was determined to address a need in the pharmaceutical and chemical markets that was not being served by the existing approaches to protein simulation and engineering. Committed to developing best-in-class antibody and protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases, Zymeworks set out to create a platform that was commercially relevant and that reflected the most recent advances in protein biochemistry and computing architecture.